Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 23, 2005, Pages 5266-5269

  Gu, Xin ^a   Dragovic, Jasminka ^a   Koo, Gloria C ^a   Koprak, Sam L ^a   Legrand, Cheryl ^a   Mundt, Steven S ^a   Shah, Kashmira ^a   Springer, Marty S ^a   Tan, Eugene Y ^a   Thieringer, Rolf ^a   Hermanowski Vosatka, Anne ^a   Zokian, Hratch J ^a   Balkovec, James M ^a   Waddell, Sherman T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

11 HSD1; 11 HSD2; 11 Hydroxysteroid dehydrogenase type I; Bicyclo 2.2.2 octyltriazole; Cortisol; Cortisone; Glucocorticoids; Heterocycle; Imidazole; Metabolic syndrome; Oxadiazole; Pharmacodynamic assay; Pharmacokinectics; Triazole

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; TRIAZOLE DERIVATIVE;

ARTICLE; DRUG ACTIVITY; HUMAN; INHIBITION KINETICS; METABOLIC SYNDROME X; MOUSE; NONHUMAN; RAT; TREATMENT INDICATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ENZYME INHIBITORS; HUMANS; METABOLIC SYNDROME X; MICE; TRIAZOLES;

EID: 26844460594     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.08.052     Document Type: Article

References (18)

1. G. Reaven Circulation 106 2002 286
2. J.R. Seckl, and B.R. Walker Trends Endocrinol. Metab. 15 2004 418 and references therein
3. J.S. Seckl, and B.R. Walker Endocrinology 142 2001 1371
4. N.M. Morton, J.M. Paterson, H. Masuzaki, M.C. Holmes, B. Staels, C. Fievet, B.R. Walker, J.S. Flier, J.J. Mullins, and J.R. Seckl Diabetes 53 2004 931
5. Y. Kotelevtsev, M.C. Holmes, and A. Burchell Proc. Natl. Acad. Sci. 94 1997 14924
6. N.M. Morton, M.C. Holmes, and C. Fievet J. Biol. Chem. 276 2001 41293
7. M.C. Holmes, Y. Kotelevtsev, J.J. Mullins, and J.R. Seckl Mol. Cell. Endocrinol. 171 2001 15
8. H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J. Flier Science 294 2001 2166
9. H. Masuzaki, H. Yamamoto, C.J. Kenyon, J.K. Elmquist, N.M. Morton, J.M. Paterson, H. Shinyama, M.G.F. Sharp, S. Fleming, J.J. Mullins, J.R. Seckl, and J.S. Flier J. Clin. Invest. 112 2003 83
10. J.M. Paterson, N.M. Morton, C. Fievet, C.J. Kenyon, M.C. Holmes, B. Staels, J.R. Seckl, and J.J. Mullins Procd. Natl. Acad. Sci. 101 2004 7088
11. For a review on patents, see the following: C. Fotsch, B.C. Askew, and J.J. Chen Expert Opin. Ther. Pat. 3 2005 289
12. For details of enzymatic assays and mouse PD assays see: A. Hermanowski-Vosatka, J. Balkovec, K. Cheng, H.Y. Chen, M. Hernandez, G.C. Koo, C.B. Le Grand, Z. Li, J.M. Metzger, S.S. Mundt, H. Noonan, C.N. Nunes, S.H. Olson, B. Pikounis, N. Ren, N. Robertson, J.M. Schaeffer, K. Shah, M.S. Springer, A.M. Strack, M. Strowski, K. Wu, T. Wu, J. Xiao, B.B. Zhang, S.D. Wright, and R. Thieringer J. Exp. Med. 2005 202
13. For mouse and rat liver microsomal studies, parent compound (2 μM) was incubated in liver microsomal suspension (1 mg protein/mL of 0.1 M phosphate buffer containing 1 mM EDTA at pH 7.4) containing 5 mM NADPH at 37°C for 1 h. The major oxidative metabolite (hydroxylation of the ω-1 carbon on the 5-carbon alkyl chain) was biosynthesized via incubation of parent compound (2 mM) in recombinant rCYP-2C11 suspension (1 mg protein/mL) containing NADPH regenerating system at 37°C for 24 h. LC/MS and NMR were used to identify the structure of the metabolite (unpublished results).
14. E.W. Della, and J. Tsanaktsidis Aust. J. Chem. 38 1985 1705
15. G. Nuding, F. Vogtle, K. Danielmeier, and E. Steckhan Synthesis 1996 71
16. G. Liang, and D. Feng Tetrahedron Lett. 37 1996 6627
17. For synthesis, see: T. Isobe, and T. Ishikawa J. Org. Chem. 64 1999 6989
18. For synthesis, see: L. Poitout, P. Roubert, M.-O. Contour-Galcera, C. Moinet, J. Lannoy, J. Pommier, P. Plas, D. Biggs, and C. Thurieau J. Med. Chem. 44 2001 2990